PLG and lung cancer: The anticancer functions of angiostatin have been studied in several cancer types such as lung cancer, brain cancer, colon cancer, breast cancer, etc. With successful completion of PhaseI/II clinical trials of angiostatin for patients with progressive metastatic cancer and non-small-cell lung cancer, the results from phase III clinical trials of angiostatin are awaited in anticipation that the study would be completed by June 2012 as scheduled.